Allardyce Randall A, Bagshaw Philip F, Frampton Christopher M, Frizelle Francis A, Hewett Peter J, Rieger Nicholas A, Smith J Shona, Solomon Michael J, Stevenson Andrew R L
Department of Surgery, University of Otago, Christchurch, New Zealand.
ANZ J Surg. 2011 Mar;81(3):125-31. doi: 10.1111/j.1445-2197.2010.05433.x. Epub 2010 Aug 16.
This paper describes the distinctions between major surgical and pharmaceutical trials and questions the application of a common ethical paradigm to guide their conduct and reporting.
Surgical trials differ from other trials in cumulative therapeutic effects, operator dependence, the clinical setting, interdependence of short- and long-term outcomes, and equipoise. A principal tenant of randomized controlled trial management is the maintenance of interim data confidentiality. Its application to complete surgical short-term data is examined across a variety of common clinical trial circumstances that influence data integrity and the reliability of conclusions regarding the benefit-to-risk profile of experimental interventions.
Complete perioperative results describe important treatment ends that cannot influence primary outcomes. These short-term results may inform patient consent, teaching and provide valuable procedural insights to surgeons outside trial precincts.
Structured experimentation standards are necessary. But, the common paradigm applied across all clinical trials and the prohibition on short term data reporting may not serve the achievement of safe and effective advancements in surgery.
本文描述了主要外科手术试验和药物试验之间的区别,并对应用共同的伦理范式来指导其实施和报告提出质疑。
外科手术试验在累积治疗效果、术者依赖性、临床环境、短期和长期结果的相互依赖性以及 equipoise 方面与其他试验不同。随机对照试验管理的一个主要原则是保持中期数据的保密性。在各种影响数据完整性以及关于实验性干预措施的风险效益概况结论可靠性的常见临床试验情况下,研究了其在完整外科短期数据中的应用。
完整的围手术期结果描述了重要的治疗终点,这些终点不会影响主要结果。这些短期结果可为患者同意、教学提供信息,并为试验区域之外的外科医生提供有价值的手术见解。
结构化的实验标准是必要的。但是,适用于所有临床试验的共同范式以及对短期数据报告的禁止可能不利于实现外科手术安全有效的进展。